Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro.

Drug metabolism and disposition: the biological fate of chemicals - 1 Dec 2009

Rudberg I, Reubsaet J L E, Hermann M, Refsum H, Molden E

Abstract excerpt

Systemic exposure of the antidepressant S-citalopram (escitalopram, SCIT) differs several-fold according to variable cytochrome P450 2C19 activity, demonstrating the importance of this enzyme for the metabolic clearance of SCIT in vivo. However, previous studies have indicated that the involvement of CYP2C19 in formation of the metabolite N-desmethyl S-citalopram (SDCIT) is limited. Therefore, the purpose of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biotransformation

Share to Citalopram

Share to Cytochrome P-450 CYP2C19

Share to Microsomes

Share to Propionates

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 19773541
DOI: 10.1124/dmd.109.029355

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro.PMID 19773541Read ↗

Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.Semantic proximity Read ↗

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.Semantic proximity Read ↗

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real-World Setting.Semantic proximity Read ↗

Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.Semantic proximity Read ↗

Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.Semantic proximity Read ↗

Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.Semantic proximity Read ↗

Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort StudySemantic proximity Read ↗

Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.Semantic proximity Read ↗

Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.Semantic proximity Read ↗

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.Semantic proximity Read ↗

Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity.Semantic proximity Read ↗

CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.